A Pilot Study of Oral Tinidazole for Women With Recurrent Bacterial Vaginosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00324142
Recruitment Status :
(Study Terminated Prematurely)
This is a study of the drug tinidazole for women with recurrent bacterial vaginosis. Half of the participants will get the drug for 10 days, the other half will get the drug for 10 days and then twice a week for 12 weeks.
Condition or disease
Recurrent Bacterial Vaginosis
Drug: Oral tinidazole
This study will recruit 60 women with recurrent bacterial vaginosis. These women must have a current infection to be enrolled in the study and have had two other infections within the past 12 months. After initial screening to make sure that the vaginal symptoms are due to bacterial vaginosis and not the results of a different infection, all of the women will receive tinidazole (a drug that is similar to metronidazole) by mouth for 10 days. At the end of the 10 days, patients will be re-examined. Those women who are free of bacterial vaginosis will enter the second phase of the study, where half of the patients will continue to take tinidazole twice a week for twelve weeks and the other half will take no medication. During this time participants will be examined by the study doctor every 4 weeks to see how effective the treatment has been at preventing the recurrence of bacterial vaginosis. At the end of the 12 weeks, women who are still free of bacterial vaginosis will be seen for 3 more visits over 3 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 45 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Current infection with bacterial vaginosis
2 previous episodes of bacterial vaginosis within the past 12 months
Willing to use contraception
Able to swallow pills
Willing to refrain from douching or using vaginal products
Willing to refrain from alcohol consumption 24 hours before and for 72 hours after taking study medication (tinidazole)
Women with same sex partners
Menstruating at initial exam
Presence of yeast, a sexually transmitted disease, or other vaginal infection
Purulent cervical discharge
Use of any drug for bacterial vaginosis or yeast within the past 2 weeks prior to enrollment
Pregnant or nursing
Taking blood thinners (anticoagulation therapy)
Use of any investigational drug within the previous 30 days